Advances in Targeted Therapy for Metastatic Prostate Cancer

The authors highlight the role of poly-ADP-ribose-polymerase inhibitors in metastatic prostate cancer, emerging strategies to target the androgen receptor, and innovative therapies aimed at cell surface proteins, including radioligand therapies, bispecific T cell engagers, and antibody–drug conjugates.